Doximity buys Pathway Medical for $63 million to help doctors get AI-powered answers
Pathway has built an AI-powered clinical reference tool that doctors can use to ask questions about guidelines, drugs and trials. Pathway's answers are synthesized from medical literature, and Doximity said the Montreal-based startup has one of the largest structured datasets in medicine.
Doximity's platform, which for years was described as LinkedIn for doctors, helps clinicians stay current on medical news, manage paperwork, find referrals and carry out telehealth appointments with patients. Through its acquisition of Pathway, Doximity hopes doctors will also turn to the platform to answer their clinical questions.
"We hunted high and low, and I think we found the best company in the space at answering physicians' questions using AI, and it wasn't in Silicon Valley," Jeff Tangney, Doximity's co-founder and CEO, told CNBC in an interview.
The deal closed in late July for a cash consideration of $26 million and up to $37 million in additional equity grants, Doximity said.
Doximity's integration with Pathway is well underway, Tangney said, and the companies are testing a combined product with thousands of doctors.
Doximity already has a free AI product, Doximity GPT, that doctors can use to generate insurance letters and summarize patient charts and reports. Pathway will bring additional "robustness" to the data that Doximity has on the back end, said Dr. Amit Phull, Doximity's chief clinical experience officer.
"What Pathway brings to this party or this marriage is that they have a very, very robust back-end data set that ties dosages to guidelines to literature to citations," Phull told CNBC in an interview.
Pathway's model scored 96% on the U.S. Medical Licensing Examination benchmark, Doximity said, which doctors have to take to prove that they understand and can apply medical knowledge.
Doximity, which went public in 2021, has seen its stock climb 8% this year after soaring 90% in 2024. The company has a market cap of about $11 billion.
Doximity is holding its quarterly conference call with investors to discuss its fiscal first-quarter results on Thursday at 5 p.m. ET.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
26 minutes ago
- CNBC
Family office deal-making slides with some bright spots in Europe
A version of this article first appeared in CNBC's Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Private investment firms of the ultra-rich once again dialed back their deal-making in July. Family offices made only 42 direct investments last month, down nearly 60% on an annual basis, according to data provided exclusively to CNBC by private wealth platform Fintrx. While the drop in July was especially steep, uncertainty over President Donald Trump 's tariffs has weighed on deal flow for months. Family office investors made 32% fewer direct investments in the first half of 2025 , per Fintrx. For those family offices that are still making deals, tariff anxieties have prompted more, including American firms, to increasingly invest overseas, advisors told CNBC . Nearly one-third of last month's direct investments were made in companies based in Europe, according to Fintrx. Former Google CEO Eric Schmidt's Hillspire invested in two AI startups based in Paris, document processor Retab and robotics firm Genesis AI, which also has an office in Palo Alto, California. Robin Lauber, CEO and co-founder of Swiss family office Infinitas Capital, told Inside Wealth that his family office has had a busier year so far in 2025 than the previous two years. Infinitas Capital, originally formed to manage the Lauber family's Swiss residential real estate assets, backed xAI and SpaceX in January and March, respectively, through its secondaries arm Opportuna. He told CNBC that he expects three portfolio companies to go public on Swedish or German exchanges by the end of the year. In July, Infinitas made its 12th direct startup investment of 2025, co-leading a $5 million pre-Series A round for Berlin-based lingerie and hosiery brand Saint Sass. The funds will be used to launch new categories like swimwear and expand further into the U.S. and U.K. Despite the market volatility, Lauber has a positive outlook, citing recent record IPOs and the likelihood of interest rate cuts in the U.S. He also anticipates that the Trump administration will moderate its economic policy before the midterm elections in 2026. "We are actually quite optimistic about the current environment and investing now," said the 32-year-old third-generation heir. "From an allocation point of view, I think it's actually a good time." Infinitas has also been able to make opportunistic investments thanks to the market turmoil. Infinitas-backed Kanaan Sellers Group, a conglomerate of ecommerce brands spanning kitchen appliances and outdoor furniture, has been able to "roll up assets really nicely," he said. "VCs or more institutional startup investors have been very reluctant to deploy into consumer businesses and asset-heavy businesses lately," he said. "These companies have had to adapt and look for more patient capital raising from family offices and high-net-worth individuals."
CNBC
26 minutes ago
- CNBC
UAE, Russia laud relations, pledging to double trade
Russian President Vladimir Putin hosted his UAE counterpart, President Mohammed bin Zayed Al Nahyan in Moscow on Thursday, with the countries pledging to double trade over the next five years. CNBC's Natasha Turak has been covering the relationship between the two nations and joins Squawk Box Europe with the details.
Yahoo
an hour ago
- Yahoo
Arm Holdings plc (ARM) Had To Guide Up, Says Jim Cramer
We recently published . Arm Holdings plc (NASDAQ:ARM) is one of the stocks Jim Cramer recently discussed. Arm Holdings plc (NASDAQ:ARM) is a British semiconductor design company whose design blocks enable chip designers to create their products. Its shares have gained 8% year-to-date but dipped by 15.8% between late July and August start after the firm's second quarter midpoint revenue forecast of $1.06 billion only managed to meet analyst estimates. Investors were expecting Arm Holdings plc (NASDAQ:ARM) to beat the estimates to showcase tailwinds from AI revenue. As part of his remarks, Cramer mentioned the forecast: 'Now Rene Haas, not prideful with a quarter that I thought was okay. But the stock is down 14%. Photo by Vishnu Mohanan on Unsplash The CNBC TV host had previously discussed Arm Holdings plc (NASDAQ:ARM) in February. Here is what he said: 'Tomorrow, we're going to hear from Arm. And you're going to hear Arm saying listen we're winning that arms race in CPUs too. So there's just a lot of them and they have a confluence of things with Jensen. But I just come back and say, Rene Haas doing better, at Arm, Jensen Huang doing better in NVIDIA.' While we acknowledge the potential of ARM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. 登入存取你的投資組合
